Corrigendum to “Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study” [eBioMedicine 83 (2022) 104208]

• Authors: Al Ozonoff, Boston Children's Hospital; Joanna Shaenman, University of California, Los Angeles; Naresh Doni Jayavelu, Benaroya Research Institute; Carly E. Milliren, Boston Children's Hospital; Carolyn S. Calfee, University of California, San Francisco; Charles B. Cairns, Drexel University; Monica Kraft, University of Arizona; Lindsey R. Baden, Boston Children's Hospital; Albert C. Shaw, Yale University; Florian Krammer, Icahn School of Medicine at Mount Sinai; Harm van Bakel, Icahn School of Medicine at Mount Sinai; Denise A. Esserman, Yale University; Shanshan Liu, Boston Children's Hospital; Ana Fernandez Sesma, Icahn School of Medicine at Mount Sinai; Viviana Simon, Icahn School of Medicine at Mount Sinai; david A. Hafler, Yale University; Ruth R. Montomery, Yale University; Steven H. Kleinstein, Yale University; Ofer Levy, Harvard University; Chris Bime, University of Arizona; Elias K. Haddad, Drexel University; David J. Erle, University of California, San Francisco; bali Pulendran, Stanford University; Kari C. Nadeau, Stanford University; Mark M. davis, Stanford University; Catherin L. Hough, Oregon Health Sciences University; William B. Messer, Oregon Health Sciences University; Nelson I. Agudelo Higuita, Oklahoma University; Jordan P. Metcalf, Oklahoma University; Mark A. Atkinson, University of Florida, Gainesville; Scott C. Brakenridge, University of Florida, Gainesville; David Corry, Baylor College of Medicine; Farrah Kheradmand, Baylor College of Medicine; Lauren I.R. Ehrlich, University of Texas, Austin; esther Melamed, University of Texas, Austin; Grace A. McComsey, Case Western Reserve University; Rafick Sekaly, Case Western Reserve University; Joann Diray-Arce, Boston Children's Hospital; Bjoern Peters, La Jolla Institute for Immunology; Alison D. Augustine, National Institutes of Health; Elaine F. Reed, University of California, Los Angeles; Matthew C. Altman, Benaroya Research Institute; Nadine Rouphael, Emory University
• Journal Title: eBioMedicine
• Volume: Volume 98
• Publisher: The Lancet Discovery Science | 2023-11-01, Pages 104860-None
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.ebiom.2023.104860
• Subjects: Biology, Biostatistics; Biology, Virology
• Keywords: COVID-19; SARS-CoV-2; Viral load; Antibody

Abstract

As part of our internal review, we identified a point to be clarified in the methods. The omitted step involves the reclassification of all deaths to the most severe category of outcome trajectories (trajectory group 5), and corresponding reclassification of non-deaths in this category to the adjacent, less severe category (trajectory group 4). This is implied by our use of the descriptor ‘fatal’ for the most severe category, but our description of methods omits the step to reclassify participants.